ReNeuron Group (OTCMKTS:RNUGF) versus Randstad (OTCMKTS:RANJY) Financial Review

ReNeuron Group (OTCMKTS:RNUGF) and Randstad (OTCMKTS:RANJY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Risk & Volatility

ReNeuron Group has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Randstad has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for ReNeuron Group and Randstad, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
Randstad	0	1	0	2	3.33

Profitability

This table compares ReNeuron Group and Randstad’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
Randstad	0.53%	9.79%	3.71%

Earnings and Valuation

This table compares ReNeuron Group and Randstad”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	$640,000.00	0.10	-$6.52 million	N/A	N/A
Randstad	$26.11 billion	0.29	$133.11 million	$0.32	65.14

Randstad has higher revenue and earnings than ReNeuron Group.

Insider and Institutional Ownership

0.0% of Randstad shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Randstad beats ReNeuron Group on 10 of the 10 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About Randstad

Randstad N.V. provides solutions in the field of work and human resources (HR) services. The company provides temporary staffing and permanent placement services; job posting; and résumé services on digital platforms. It offers inhouse, enterprise and digital, and tech suite services. In addition, the company provides managed services programs, recruitment process outsourcing, outplacement and career development, and online talent acquisition. It has operations in North America, France, the Netherlands, Germany, Belgium, Luxembourg, Italy, Iberia, other European countries, and internationally. The company was formerly known as Randstad Holding NV and changed its name to Randstad N.V. in April 2018. Randstad N.V. was founded in 1960 and is headquartered in Diemen, the Netherlands.